HOME >> BIOLOGY >> NEWS
VIB scientist receives major research grant

Leuven, Belgium − On 10 July, Thierry VandenDriessche, a researcher at VIB and the Katholieke Universiteit Leuven, is to receive the Hemophilia Research Award for his research on hemophilia − a hereditary disorder affecting coagulation of the blood. The research grant, for the amount of 200,000 USD, is being presented by Bayer at a meeting of the International Society of Thrombosis & Hemostasis in Geneva. With this prize, Bayer is lending its support to research on hemophilia. Thierry VandenDriessche and his colleague Marinee Chuah are investigating the possibilities of improved treatments for hemophilia, including gene therapy.

Hemophilia

Hemophilia is a hereditary disorder in which certain coagulation factors in the blood are missing. This causes frequent bleeding in the muscles and joints, with tissue damage as a result. If the disorder is left untreated, the blood will no longer be able to coagulate, which can indirectly even lead to death. In 85% of the patients, there is a shortage of coagulation factor VIII. This condition is called hemophilia A. The rest of the patients most often have a shortage of coagulation factor IX (hemophilia B). The disorder has a frequency of 1 in 10,000. In the 20th century, hemophilia was one of the most well-known and extensively studied hereditary disorders, as it afflicted several royal families. Alexis, the only son of Russian czar Nicolas II, was perhaps the most famous hemophilia patient.

Gene therapy

Regular injection of the right coagulation factor is usually the only possible treatment for hemophilia patients. Gene therapy might well be an alternative solution. In this approach to curing the disorder, a malfunctioning gene (part of the DNA) is replaced by a properly functioning gene. VIB researchers Thierry VandenDriessche and Marinee Chuah are the first to have achieved a sustained gene therapy cure for hemophilia A in mice. In the mice with hemophilia A, the r
'"/>

Contact: Evy Vierstraete
info@vib.be
329-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
9-Jul-2007


Page: 1 2

Related biology news :

1. Doernbecher Childrens Hospital scientist earns coveted Javits award
2. UK scientists working to help cut ID theft
3. Smithsonian scientists show differing patterns of rainforest biodiversity
4. Weizmann Institute scientists discover a control mechanism for metastasis
5. Cornell scientists link E. coli bacteria to Crohns disease
6. UCLA scientists produce functioning neurons from human embryonic stem cells
7. ASBMB taps 8 scientists and 1 politician for top awards
8. UF, French scientists seek test to detect gene doping in athletes
9. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
10. Universes stringy birth revealed by young Czech scientist in EURYI winning project
11. Forsyth scientists gain new understanding of adult stem cell regulation

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: VIB scientist receives major research grant

(Date:5/23/2013)... By discovering the new mechanism by which estrogen suppresses ... revealed a potential new approach toward treating certain liver ... and colleagues believe they are changing long-held views in ... issue of the journal Science Signaling . , ... years has been that only receptors located in the ...
(Date:5/23/2013)... Some prostate cancer patients unnecessarily undergo surgery or ... differences between slow-growing and aggressive forms of the ... Johns Hopkins Medical Institutes are developing technology that ... opt for relatively mild treatments or take drastic ... Anant Madabhushi, an associate professor of biomedical engineering ...
(Date:5/23/2013)... world are billions of animal and plant specimens from ... all stacked, stored and preserved in jars and collection ... critical to understanding how the Earth,s biodiversity is changing ... if only the information were easily accessible. , A ... of a team from the University of Colorado Boulder, ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
(Date:5/23/2013)... -- BioScrip, Inc. (NASDAQ: BIOS ) today announced ... Global Healthcare Conference to be held June 3-6, 2013 ... Richard Smith , President and Chief Executive ... Financial Officer, will present on Monday, June 3, 2013 ... About BioScrip BioScrip, Inc. provides comprehensive infusion and ...
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan Racing ... cord blood stem cell banking and therapeutics, announced today ... No. 16 Acorn Stairlifts Indy car driven by ... remainder of the IZOD IndyCar 2013 season.   ... work to support awareness of umbilical cord blood banking ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... May 23, 2013 The New Jersey ... industries, Black Data Processing Associates (BDPA), is hosting its ... 8, 2013. This all-day event will encourage students and ... the ins and outs from many of the industries’ ... at the New Jersey Institute of Technology, the event ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2
Cached News: